{"downloaded": true, "htmlmade": false, "full": {"id": "29859176", "source": "MED", "pmid": "29859176", "pmcid": "PMC7001723", "fullTextIdList": {"fullTextId": "PMC7001723"}, "doi": "10.1016/j.stem.2018.05.018", "title": "Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia.", "authorString": "Choi MY, Widhopf GF, Ghia EM, Kidwell RL, Hasan MK, Yu J, Rassenti LZ, Chen L, Chen Y, Pittman E, Pu M, Messer K, Prussak CE, Castro JE, Jamieson C, Kipps TJ.", "authorList": {"author": [{"fullName": "Choi MY", "firstName": "Michael Y", "lastName": "Choi", "initials": "MY", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA; CIRM Alpha Stem Cell Clinic at University of California, San Diego, and Sanford Stem Cell Clinical Center, La Jolla, CA 92037-0695, USA; Division of Hematology Oncology, Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA."}}}, {"fullName": "Widhopf GF 2nd", "firstName": "George F", "lastName": "Widhopf", "initials": "GF", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA; Division of Hematology Oncology, Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA."}}}, {"fullName": "Ghia EM", "firstName": "Emanuela M", "lastName": "Ghia", "initials": "EM", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA."}}}, {"fullName": "Kidwell RL", "firstName": "Reilly L", "lastName": "Kidwell", "initials": "RL", "authorId": {"@type": "ORCID", "#text": "0000-0002-3358-030X"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA; CIRM Alpha Stem Cell Clinic at University of California, San Diego, and Sanford Stem Cell Clinical Center, La Jolla, CA 92037-0695, USA."}}}, {"fullName": "Hasan MK", "firstName": "Md Kamrul", "lastName": "Hasan", "initials": "MK", "authorId": {"@type": "ORCID", "#text": "0000-0002-1271-4428"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA."}}}, {"fullName": "Yu J", "firstName": "Jian", "lastName": "Yu", "initials": "J", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA."}}}, {"fullName": "Rassenti LZ", "firstName": "Laura Z", "lastName": "Rassenti", "initials": "LZ", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA; Division of Hematology Oncology, Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA."}}}, {"fullName": "Chen L", "firstName": "Liguang", "lastName": "Chen", "initials": "L", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA."}}}, {"fullName": "Chen Y", "firstName": "Yun", "lastName": "Chen", "initials": "Y", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA."}}}, {"fullName": "Pittman E", "firstName": "Emily", "lastName": "Pittman", "initials": "E", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA; Division of Biostatistics and Bioinformatics, Department of Family Medicine and Public Health, University of California, San Diego, La Jolla, CA 92093-0901, USA."}}}, {"fullName": "Pu M", "firstName": "Minya", "lastName": "Pu", "initials": "M", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA; Division of Biostatistics and Bioinformatics, Department of Family Medicine and Public Health, University of California, San Diego, La Jolla, CA 92093-0901, USA."}}}, {"fullName": "Messer K", "firstName": "Karen", "lastName": "Messer", "initials": "K", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA; Division of Biostatistics and Bioinformatics, Department of Family Medicine and Public Health, University of California, San Diego, La Jolla, CA 92093-0901, USA."}}}, {"fullName": "Prussak CE", "firstName": "Charles E", "lastName": "Prussak", "initials": "CE", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA."}}}, {"fullName": "Castro JE", "firstName": "Januario E", "lastName": "Castro", "initials": "JE", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA; Division of Blood and Marrow Transplantation, Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA."}}}, {"fullName": "Jamieson C", "firstName": "Catriona", "lastName": "Jamieson", "initials": "C", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA; CIRM Alpha Stem Cell Clinic at University of California, San Diego, and Sanford Stem Cell Clinical Center, La Jolla, CA 92037-0695, USA; Division of Hematology Oncology, Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA; Division of Regenerative Medicine, Department of Medicine, University of California, San Diego, La Jolla, CA 92037-0695, USA. Electronic address: cjamieson@ucsd.edu."}}}, {"fullName": "Kipps TJ", "firstName": "Thomas J", "lastName": "Kipps", "initials": "TJ", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA; CIRM Alpha Stem Cell Clinic at University of California, San Diego, and Sanford Stem Cell Clinical Center, La Jolla, CA 92037-0695, USA; Division of Hematology Oncology, Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA. Electronic address: tkipps@ucsd.edu."}}}]}, "authorIdList": {"authorId": [{"@type": "ORCID", "#text": "0000-0002-1271-4428"}, {"@type": "ORCID", "#text": "0000-0002-3358-030X"}]}, "dataLinksTagsList": {"dataLinkstag": ["related_data", "supporting_data", "altmetrics"]}, "journalInfo": {"issue": "6", "volume": "22", "journalIssueId": "2691315", "dateOfPublication": "2018 Jun", "monthOfPublication": "6", "yearOfPublication": "2018", "printPublicationDate": "2018-06-01", "journal": {"title": "Cell stem cell", "ISOAbbreviation": "Cell Stem Cell", "medlineAbbreviation": "Cell Stem Cell", "NLMid": "101311472", "ISSN": "1934-5909", "ESSN": "1875-9777"}}, "pubYear": "2018", "pageInfo": "951-959.e3", "abstractText": "Cirmtuzumab is a humanized monoclonal antibody (mAb) that targets ROR1, an oncoembryonic orphan receptor for Wnt5a found on cancer stem cells (CSCs). Aberrant expression of ROR1 is seen in many malignancies and has been linked to Rho-GTPase activation and cancer stem cell self-renewal. For patients with chronic lymphocytic leukemia (CLL), self-renewing, neoplastic B cells express ROR1 in 95% of cases. High-level leukemia cell expression of ROR1 is associated with an unfavorable prognosis. We conducted a phase 1 study involving 26 patients with progressive, relapsed, or refractory CLL. Patients received four biweekly infusions, with doses ranging from 0.015 to 20\u00a0mg/kg. Cirmtuzumab had a long plasma half-life and did not have dose-limiting toxicity. Inhibition of ROR1 signaling was observed, including decreased activation of RhoA and HS1. Transcriptome analyses showed that therapy inhibited CLL stemness gene expression signatures in\u00a0vivo. Cirmtuzumab is safe and effective at inhibiting tumor cell ROR1 signaling in patients with CLL.", "affiliation": "Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA; CIRM Alpha Stem Cell Clinic at University of California, San Diego, and Sanford Stem Cell Clinical Center, La Jolla, CA 92037-0695, USA; Division of Hematology Oncology, Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.", "publicationStatus": "ppublish", "language": "eng", "pubModel": "Print", "pubTypeList": {"pubType": ["research-article", "Clinical Trial, Phase I", "Journal Article"]}, "grantsList": {"grant": [{"grantId": "P01 CA081534", "agency": "NCI NIH HHS", "acronym": "CA", "orderIn": "0"}, {"grantId": "P30 CA023100", "agency": "NCI NIH HHS", "acronym": "CA", "orderIn": "0"}]}, "meshHeadingList": {"meshHeading": [{"majorTopic_YN": "N", "descriptorName": "Humans"}, {"majorTopic_YN": "N", "descriptorName": "Infusions, Intravenous"}, {"majorTopic_YN": "N", "descriptorName": "Signal Transduction", "meshQualifierList": {"meshQualifier": [{"abbreviation": "DE", "qualifierName": "drug effects", "majorTopic_YN": "Y"}, {"abbreviation": "GE", "qualifierName": "genetics", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Structure-Activity Relationship"}, {"majorTopic_YN": "N", "descriptorName": "Dose-Response Relationship, Drug"}, {"majorTopic_YN": "N", "descriptorName": "Drug Tolerance"}, {"majorTopic_YN": "N", "descriptorName": "Leukemia, Lymphocytic, Chronic, B-Cell", "meshQualifierList": {"meshQualifier": [{"abbreviation": "DT", "qualifierName": "drug therapy", "majorTopic_YN": "Y"}, {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}, {"abbreviation": "PA", "qualifierName": "pathology", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Receptor Tyrosine Kinase-like Orphan Receptors", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AI", "qualifierName": "antagonists & inhibitors", "majorTopic_YN": "Y"}, {"abbreviation": "GE", "qualifierName": "genetics", "majorTopic_YN": "N"}, {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Antibodies, Monoclonal, Humanized", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "N"}, {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "Y"}, {"abbreviation": "PD", "qualifierName": "pharmacology", "majorTopic_YN": "N"}, {"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "N"}, {"abbreviation": "CH", "qualifierName": "chemistry", "majorTopic_YN": "N"}]}}]}, "chemicalList": {"chemical": [{"name": "ROR1 protein, human", "registryNumber": "EC 2.7.10.1"}, {"name": "Receptor Tyrosine Kinase-like Orphan Receptors", "registryNumber": "EC 2.7.10.1"}, {"name": "Antibodies, Monoclonal, Humanized", "registryNumber": "0"}, {"name": "cirmtuzumab", "registryNumber": "FEH7RQ7B3J"}]}, "subsetList": {"subset": {"code": "IM", "name": "Index Medicus"}}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1016/j.stem.2018.05.018"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC7001723"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "pdf", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC7001723?pdf=render"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1016/j.stem.2018.05.018"}]}, "isOpenAccess": "N", "inEPMC": "Y", "inPMC": "N", "hasPDF": "Y", "hasBook": "N", "hasSuppl": "Y", "citedByCount": "36", "hasData": "Y", "hasReferences": "Y", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "Y", "dbCrossReferenceList": {"dbName": "EMBL"}, "hasLabsLinks": "Y", "authMan": "Y", "epmcAuthMan": "N", "nihAuthMan": "Y", "manuscriptId": "NIHMS1068593", "hasTMAccessionNumbers": "Y", "tmAccessionTypeList": {"accessionType": "geo"}, "dateOfCompletion": "2019-10-08", "dateOfCreation": "2018-06-03", "firstIndexDate": "2018-06-03", "fullTextReceivedDate": "2020-10-21", "dateOfRevision": "2020-02-06", "firstPublicationDate": "2018-06-01"}, "abstract": "Cirmtuzumab is a humanized monoclonal antibody (mAb) that targets ROR1, an oncoembryonic orphan receptor for Wnt5a found on cancer stem cells (CSCs). Aberrant expression of ROR1 is seen in many malignancies and has been linked to Rho-GTPase activation and cancer stem cell self-renewal. For patients with chronic lymphocytic leukemia (CLL), self-renewing, neoplastic B cells express ROR1 in 95% of cases. High-level leukemia cell expression of ROR1 is associated with an unfavorable prognosis. We conducted a phase 1 study involving 26 patients with progressive, relapsed, or refractory CLL. Patients received four biweekly infusions, with doses ranging from 0.015 to 20\u00a0mg/kg. Cirmtuzumab had a long plasma half-life and did not have dose-limiting toxicity. Inhibition of ROR1 signaling was observed, including decreased activation of RhoA and HS1. Transcriptome analyses showed that therapy inhibited CLL stemness gene expression signatures in\u00a0vivo. Cirmtuzumab is safe and effective at inhibiting tumor cell ROR1 signaling in patients with CLL.", "journaltitle": "Cell stem cell", "authorinfo": ["Choi MY", "Widhopf GF 2nd", "Ghia EM", "Kidwell RL", "Hasan MK", "Yu J", "Rassenti LZ", "Chen L", "Chen Y", "Pittman E", "Pu M", "Messer K", "Prussak CE", "Castro JE", "Jamieson C", "Kipps TJ"], "title": "Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia."}